MediBeacon’s extensive portfolio of light-activated agents is the foundation for a pipeline of potential medical innovations. Application of MediBeacon technology in gastrointestinal disease is being pursued collaboratively at Washington University School of Medicine in St. Louis with funding from the Bill & Melinda Gates Foundation.
The company holds numerous patents on its light-activated agents. Focus is on bringing transformational technology into medical practice. Delivering products which can have a profoundly positive impact on both the quality and cost of patient care is always the goal.
MediBeacon Product Pipeline
Photonics plays a key role in next-generation health care, both in enhancing the ability to observe and measure symptoms and the capability to treat patients earlier with less invasive, more cost-effective methods.